COVID-19 and tuberculosis—threats and opportunities

Document Type: Research Article

Affiliations: 1: Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, UK 2: Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, University of Sydney, Sydney NSW, Australia; 3: Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal, I Med Clinic, University of Mainz, Mainz, Germany 4: Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK 5: Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia 6: Foundation Congolaise pour la Recherche Médicale/University Marien Ngouabi Brazzaville, Congo, Institute for Tropical Medicine/University of Tübingen, Germany 7: Ministry of Health, Lusaka, Zambia 8: National Institute of Medical Research, Dar es Salaam, Tanzania 9: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Varese, 10: Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy 11: Institute for Clinical Medicine, Faculty of Health Sciences, University of Aarhus, Denmark, Department of Melecular Medicine, University of Pavia, Italy 12: Department of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China 13: Lazzaro Spallanzani, National Institute for Infectious Diseases IRCCS, Rome, Italy 14: Hong Kong Tuberculosis, Chest and Heart Diseases Association, Hong Kong, China 15: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK, , Email: [email protected]

Publication date: August 1, 2020